Bruker 8-K

EarningsNew guidanceRestructuringImpairment / charge

Biopharma and industrial research recovered as semiconductor orders improved; management targets a return to organic growth by Q2 2026.

Filed 2026-02-12 07:00 ET

Summary

Q4 and FY2025 results with initial FY2026 guidance. FY2025 revenue grew 2.1% reported but fell 3.7% organically, while GAAP results included impairment and restructuring charges. Bruker initiated FY2026 guidance calling for a return to organic growth by Q2 and 15%–17% non-GAAP EPS growth.

Key Figures

Metric Q4 2025 Q4 2024 Y/Y
Revenue $977M $980M -0.2%
GAAP operating income $76.3M $72.1M +5.8%
Non-GAAP operating income $154M $178M -13.5%
Net income attributable to Bruker Corporation common shareholders $14.9M $13.7M +8.8%
GAAP diluted EPS $0.10 $0.09 +11.1%
Non-GAAP diluted EPS $0.59 $0.76 -22.4%
Operating cash flow $230M $190M +21.0%
Free cash flow $207M $153M +35.2%
Metric FY2025 FY2024 Y/Y
Revenue $3.44B $3.37B +2.1%
GAAP operating income $68.2M $253M -73.1%
Non-GAAP operating income $433M $518M -16.4%
Net income attributable to Bruker Corporation common shareholders $(22.5)M $113M n/m
GAAP diluted EPS $(0.15) $0.76 n/m
Non-GAAP diluted EPS $1.83 $2.41 -24.1%
Operating cash flow $134M $251M -46.6%
Free cash flow $43.3M $136M -68.2%
  • Revenue drivers: Q4 organic revenue declined 5.1%, partly offset by 0.8% growth from acquisitions and a 4.1% foreign currency tailwind. For FY2025, organic revenue declined 3.7%, while acquisitions contributed 3.5% growth and foreign currency added 2.3%. Management cited second-half recovery in biopharma and industrial research and improved semiconductor orders; Scientific Instruments’ book-to-bill exceeded 1.0 for a second consecutive quarter.
  • FY2025 GAAP results included $127M of non-cash goodwill and intangible-asset impairment charges and $77.4M of restructuring charges, primarily recorded in Q3.
  • Year-end cash was $299M vs $183M a year earlier; long-term debt was $1.85B, with $16.6M of current debt and finance lease obligations. FY2025 included $466M of long-term debt repayments and $10.0M of common-stock repurchases.

Guidance

Metric Period Guidance Prior Direction
Revenue (GAAP) FY2026 $3.57B–$3.60B; 4%–5% reported Y/Y growth; 1%–2% organic growth, ≈1.5% M&A contribution and ≈1.5% foreign currency tailwind — Initiated
EPS (non-GAAP) FY2026 $2.10–$2.15; 15%–17% Y/Y growth; 23%–25% constant-exchange-rate growth, including an ≈8% (≈$0.15) currency headwind — Initiated

Investor Takeaways

  • The FY2026 outlook assumes a mid-single-digit organic revenue decline in Q1 and a return to organic growth by Q2; quarterly organic growth will test that trajectory.
  • Bruker said it is extending major cost-saving initiatives beyond the upper end of its previous range; FY2026 margin expansion and non-GAAP EPS growth will show whether those actions deliver as planned.

The summary is written by an AI model reading the filing.

Model 005 · prompt 01d34d48e3

Feedback